ePrints

Hesperidin as a potent telomerase inhibitor: Studies on its anticancer and anti-telomerase effects

Lookup NU author(s): Dr Gabriele Saretzki

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2025Lung cancer, prevalent in both genders, is associated with elevated telomerase activity (TA). Some plant-derived molecules such as boldine, resveratrol, pterostilbene and quercetin act as telomerase blockers, reducing TA in different types of malignant cells. To test more such natural inhibitors, we investigated here whether hesperidin (HSP), a naturally occurring citrus fruit ingredient, inhibits TA and affects A549 cell growth and apoptosis. We analysed cytotoxicity, cell viability, and determined the apoptotic impact of various concentrations of HSP and curcumin (CUR) in A549 cells. Morphological features were observed by phase-contrast microscopy and a telomeric repeat amplification protocol (TRAP) assay performed to quantify TA. Cytotoxic studies of HSP and CUR on erythrocytes showed no hemolysis of cells at the concentrations tested (up to 80 μmol/ml). HSP significantly reduced TA and cell viability, in addition to an associated increase in apoptotic events in a dose-dependent manner. In addition, molecular docking experiments were conducted using telomerase crystal structure. The docking results of HSP showed a strong interaction with the active site of telomerase which was an even stronger telomerase inhibitor than the control inhibitor, CUR and possessed hydrophobic, hydrogen and van der Waals interactions. These observations advocate telomerase as an intriguing potential target for lung cancer while future studies should address the exact dose and duration of HSP use in cancer therapies in vivo.

Publication metadata

Author(s): Porika M, Tippani R, Rekulapally S, Kalam S, Poonuru RR, Manda S, Saretzki GC, Abbagani S

Publication type: Article

Publication status: Published

Journal: Food Bioscience

Year: 2025

Volume: 65

Print publication date: 01/03/2025

Online publication date: 04/02/2025

Acceptance date: 02/02/2025

ISSN (print): 2212-4292

ISSN (electronic): 2212-4306

Publisher: Elsevier Ltd

URL: https://doi.org/10.1016/j.fbio.2025.106063

DOI: 10.1016/j.fbio.2025.106063

Altmetrics

Share